Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Octreotide acetate: Phase II completed enrollment

Valera completed enrollment of 12 patients

Read the full 64 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE